- Home
- PINE vs ABEO Comparison
PINE vs ABEO Comparison
Compare PINE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | ABEO |
|---|---|---|
| Founded | 2019 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.9M | 399.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PINE | ABEO |
|---|---|---|
| Price | $21.21 | $6.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $20.10 | $20.00 |
| AVG Volume (30 Days) | 189.6K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $60,532,000.00 | $2,998,000.00 |
| Revenue This Year | $18.63 | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | $340.75 | ★ N/A |
| Revenue Growth | 15.90 | ★ 258.18 |
| 52 Week Low | $13.10 | $4.00 |
| 52 Week High | $21.32 | $7.54 |
Technical Indicators
Market Signals| Indicator | PINE | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 67.05 |
| Support Level | $18.80 | $4.97 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.56 | 0.38 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 88.51 | 81.84 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.